iiinova — where your digital self keeps evolving

Craig Gedye @craiggedye.bsky.social · 28/06/2026

Sunday at #ANZUP #ASM26 here in beautiful Adelaide starts with the Perfect Pitch, Trial Coordinators Session and ANZUP/PCFA Nurses Session. But first, coffee and thanks to Icon for supporting this essential kick-start! @anzuptrials.bsky.social @iconcancercentre.bsky.social #PCFA

000 0

Craig Gedye @craiggedye.bsky.social · 19/06/2026

People that confuse correlation with causation need to drink 8 glasses of water per day during hydration breaks xkcd.com/3260/

000 0

Craig Gedye @craiggedye.bsky.social · 18/06/2026

On World Kidney Cancer Day, it's incredible to reflect what progress has been made, but how much there is still to go. This recent paper shows what we might be possible if every person with advanced #kidneycancer could experience a complete response to immunotherapy www.ejcancer.com/article/S095...

From Andersen et al., Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC
Clinical outcomes of RCC responders and multivariable analysis. A-C) Kaplan-Meier curves for PFS (A), OS (B) and DSS (C) in RCC responders stratified by depth of response. 95% CI are reported in parentheses. D–F) Forest plots from multivariable Cox proportional hazards models showing HRs (log scale) and 95% CIs for selected clinical covariates associated with PFS (D), OS (E), and DSS (F).

010 0

Craig Gedye @craiggedye.bsky.social · 30/05/2026

Thank you once again to 347 Australians with #glioblastoma, 28 hospitals, over 70 Consortium members, the NHMRC CTC, and COGNO as we present the MAGMA trial at #ASCO #ASM26

030 0

Craig Gedye @craiggedye.bsky.social · 01/03/2026

Thank you. Agree, PSMA and PSA are just phenotypic markers that are demonstrably dispensable as mPC evolves under environmental and treatment selective pressure.

011 0

Craig Gedye @craiggedye.bsky.social · 27/02/2026

Thank you. Could you expand? PSA response vs PSMA response - is one better?

111 0

Craig Gedye @craiggedye.bsky.social · 30/11/2025

The kids have (sadly) aged out of Lego advent calendars, so thanks again to @FreseniusKabi for shipping their IV saline in such strong and repurposable cardboard boxes!

030 0

Craig Gedye @craiggedye.bsky.social · 26/11/2025

Inferred prospective evidence from other settings? E.g. elective surgery pubmed.ncbi.nlm.nih.gov/35418085/ and peri-treatment for HNSCC www.redjournal.org/article/S036...

100 0

Craig Gedye @craiggedye.bsky.social · 25/11/2025

Grateful to have overheard a colleague talking about "preemptive pregabilin". Offered immediate upfront pregabilin for a patient with florid and painful shingles, with rapid improvement of pain. No prospective trials but interesting case series. 10/10 would Rx again. journals.lww.com/ejanaesthesi...

130 0

Craig Gedye @craiggedye.bsky.social · 25/11/2025

Our goal for every person, every day xkcd.com/3172/

xkcd.com

Fifteen Years

020 0

Reposted by Craig Gedye

Fumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · 20/11/2025

"Beyond respectful language, which is the minimum requirement… [this study] reinforces the broader message about maintaining respect for patients as individuals & ensuring that this is reflected in our words & deeds." @ascocancer.bsky.social @jco-asco.bsky.social @ethicsdoctorp.bsky.social

ascopubs.org

Don't Do Me Like That: Promoting Respectful Language in Oncology Research | JCO Oncology Practice

152 0

Craig Gedye @craiggedye.bsky.social · 20/10/2025

It's on my bookshelf as well, and perhaps one of the only books I actually open with any regularity.

110 0

Craig Gedye @craiggedye.bsky.social · 19/10/2025

When life gives you sour mandarins...

020 0

Craig Gedye @craiggedye.bsky.social · 15/10/2025

well done and great work congrats to you and @asharpmedonc.bsky.social the team

220 0

Craig Gedye @craiggedye.bsky.social · 21/09/2025

PRAME now useful as a routine phenotype IHC diagnostic marker as well, so many labs will be able to detect in routine care

120 0

Craig Gedye @craiggedye.bsky.social · 16/09/2025

Thanks so much to @anzuptrials.bsky.social for helping us starting putting the NZ into ANZUP - great ideas shared on the day for clinical trials for people with GU and prostate cancers in NZ and maybe also AUS as well!

141 0

Craig Gedye @craiggedye.bsky.social · 04/09/2025

Fantastic to have this critical advice for older people with cancer - thank you @crisbergerot.bsky.social @bogda-koczwara.bsky.social and team

153 0

Craig Gedye @craiggedye.bsky.social · 17/08/2025

And the infographic Research Summary as well www.nejm.org/do/10.1056/N.... Clinical trials only become healthcare if you communicate the result. Ringer's no better than saline BTW.

130 0

Reposted by Craig Gedye

Peter van Galen @vangalenlab.bsky.social · 15/08/2025

Online today! *Aging, Immune Fitness and Cancer* 🔬 Learn the latest about the intersection between these processes in @natrevcancer.nature.com 🧬 Great to work with @sandramcallister.bsky.social lab again 😁 doi.org/10.1038/s415...

0167 0

Craig Gedye @craiggedye.bsky.social · 02/08/2025

One more of my votes for the #Hottest100 #TripleJ in the #Hottest200 today... The Whitlams - Blow Up The Pokies www.youtube.com/watch?v=7B49..., still as relevant today www.theguardian.com/australia-ne...

youtube.com

The Whitlams - Blow Up The Pokies (Official Video)

YouTube video by thewhitlamsofficial

030 0

Craig Gedye @craiggedye.bsky.social · 30/07/2025

Question remains, is the abscopal effect real? Or is #RT just additive? Certainly evidence for modifying TME, intriguing data for WNT-mt patients when adding #radiotherapy to #PD1 #immunotherapy, but the idea of #RT being a 'vaccine', expanding the immune repertoire, is shown in just 1-2 patients.

020 0

Reposted by Craig Gedye

ANZUP Cancer Trials Group @anzuptrials.bsky.social · 28/07/2025

The Renal IGW is fast approaching. Concept submissions close in 1 week! Register your attendance here anzup.org.au/idea-generat... @craiggedye.bsky.social

042 0

Reposted by Craig Gedye

Ian Davis @profiand.bsky.social · 26/07/2025

Two opinions that to my surprise are either unpopular or not widely held: 1. The control arm of a randomised trial should be best standard of care. 2. A PFS benefit against an inactive comparator is not a major advance, if progressive disease is required for eligibility.

242 0

Craig Gedye @craiggedye.bsky.social · 26/07/2025

3. Despite ASCO (ascopubs.org/doi/full/10....) and FDA (www.raps.org/news-and-art...) statements that it is unethical to stick large needles into people suffering cancer, many sponsors seem to want to shove large needles into people suffering cancer; for what? To make pretty pictures for a poster?

raps.org

FDA draft guidance outlines appropriate use of tissue biopsies in clinical trials

When are tissue biopsies really needed in clinical trials of medical products? Draft guidance from the US Food and Drug Administration (FDA) offers recommendations for weighing the risks and benefits ...

110 0

Reposted by Craig Gedye

Tian Zhang, MD @tiansterzhangmd.bsky.social · 20/07/2025

Great kickoff to clinical trials workshop #ANZUP25 — #MelissaLeMesurier w patient perspective and #ChrisGianacas biostats on collaborative efforts for clinical trials. Same global themes for clinical trial development. @anzuptrials.bsky.social @craiggedye.bsky.social @profiand.bsky.social

042 0

Craig Gedye @craiggedye.bsky.social · 23/06/2025

Tremendous insights with immediate patient impact; using genomic data we can collect routinely from today's patients, we may be able to predict upfront resistance, rather than subject people to 3-4 cycles of chemo, and we might also be strategic if we know people have sensitive cancers - bravo!

000 0

Reposted by Craig Gedye

Soragni:Lab @alice.soragnilab.com · 03/06/2025

Acquired resistance limits the efficacy of cancer treatments & accounts for therapy failure in most patients. Our Roadmap explores how innovative technologies bridge the gap between fundamental research on resistance and clinical translation into actionable strategies www.nature.com/articles/s41...

nature.com

Acquired resistance in cancer: towards targeted therapeutic strategies - Nature Reviews Cancer

Acquired therapeutic resistance is a key contributor to cancer treatment failure, requiring new approaches to address its complex mechanisms. In this Roadmap, Soragni, Knudsen and colleagues discuss t...

13414 0

Reposted by Craig Gedye

Prof Haryana Dhillon @hagsie.bsky.social · 02/06/2025

Meet Cherrie, one of the earliest participants in the CHALLENGE trial, and my colleague Janette Vardy talking about what these results mean. www.9news.com.au/videos/natio...

9news.com.au

9News - Latest news and headlines from Australia and the world

Latest news and headlines from Australia and the world

021 0

Reposted by Craig Gedye

Aaron Mitchell @thewonkologist.bsky.social · 31/05/2025

Presenting at #ASCO25 today! I was expecting to find evidence that oncologists prefer more-lucrative treatments, and was surprised by our results! Clinical benefit matters, drug profit did not. Cc @dusetzinas.bsky.social

54118 0

Craig Gedye @craiggedye.bsky.social · 10/05/2025

*shared with permission. And thanks to #Telstra for mobile phone coverage in the Australian wilderness!

010 0

Craig Gedye @craiggedye.bsky.social · 09/05/2025

Thanks again Gauthier Bouche and the @AnticancerFund for support, Tom van der Hulle, Amy Rieborn and the team at @unileiden.bsky.social University Medical Center our collaborators and our site @iconcancercentre.bsky.social Learn more about the #ANZadapt trial here anzup.org.au/wp-content/u...

anzup.org.au

100 0

Craig Gedye @craiggedye.bsky.social · 09/05/2025

So grateful for all the volunteer participants in this crucial clinical trial of #adaptive #evolutionary therapy, and so grateful that we can run an important clinical trial without running people ragged with hospital visits.

100 0

Craig Gedye @craiggedye.bsky.social · 09/05/2025

#Teletrials in action: a generous and kind participant called me this week for Visit #3 of his participation in @anzuptrials.bsky.social #ANZadapt #clinicaltrial. “Where are you?”, I asked. “Let me send you a photo”, he said. How’s the serenity…

130 0

Reposted by Craig Gedye

European Medicines Agency @ema.europa.eu · 16/04/2025

🚨 Public consultations now open: help shape how medicine information is shared with patients. We are reviewing the template used for EU package leaflets. Have your say on how to make them more understandable and relevant to patients. 🔗 Learn more & share your input: europa.eu/!TCm47q

02922 0

Reposted by Craig Gedye

International Kidney Cancer Coalition @ikccorg.bsky.social · 06/04/2025

Excellent, thought-provoking presentation by Deb Maskens of IKCC on the % of patients that are not being reached by #KidneyCancer organisations and strategies to consider on how we can improve. #IKCC25 @debmaskens.bsky.social

031 0

Craig Gedye @craiggedye.bsky.social · 04/04/2025

And what about those Phillip Island little penguins... they used to be called FAIRY penguins... enough said... +10%. www.penguins.org.au

100 0

Craig Gedye @craiggedye.bsky.social · 01/04/2025

Safe travels and thank you for the ongoing good works.

010 0